IQVIA Holdings Inc. $IQV Position Increased by Equitable Trust Co.

Equitable Trust Co. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 81.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,140 shares of the medical research company’s stock after purchasing an additional 5,900 shares during the quarter. Equitable Trust Co.’s holdings in IQVIA were worth $2,496,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. boosted its holdings in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Westside Investment Management Inc. boosted its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the period. Atlantic Union Bankshares Corp bought a new position in IQVIA in the 3rd quarter worth about $36,000. Asset Dedication LLC increased its stake in shares of IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares during the period. Finally, Rothschild Investment LLC raised its holdings in shares of IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after buying an additional 124 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

NYSE:IQV opened at $162.08 on Tuesday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market cap of $27.50 billion, a P/E ratio of 20.62, a PEG ratio of 1.60 and a beta of 1.37. The business’s 50-day moving average price is $216.37 and its 200 day moving average price is $208.54.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same quarter last year, the firm posted $3.12 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IQV shares. Truist Financial decreased their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday. UBS Group decreased their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday, February 6th. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Finally, JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $231.80.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.